Reversible versus irreversible inhibition modes of ERK2: a comparative analysis for ERK2 protein kinase in cancer therapy

被引:38
|
作者
Khan, Shama [1 ]
Bjij, Imane [1 ,2 ]
Betz, Robin M. [3 ]
Soliman, Mahmoud E. S. [1 ]
机构
[1] Univ KwaZulu Natal, Sch Hlth Sci, Mol Biocomputat & Drug Design Lab, ZA-4000 Durban, South Africa
[2] Univ Cadi Ayyad, Fac Sci Semlalia, Dept Chim, Ave My Abdellah,BP2390, Marrakech, Morocco
[3] Stanford Univ, Biophys Program, Stanford, CA 94305 USA
关键词
covalent inhibition; covalent molecular dynamic simulations; irreversible/reversible inhibitors; MOLECULAR-DYNAMICS SIMULATIONS; COVALENT INHIBITORS; SIGNALING PATHWAYS; BINDING; AMBER; MM/PBSA; MAP;
D O I
10.4155/fmc-2017-0275
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Aim: Irreversible covalent drug inhibition is an emerging paradigm; however, critical gaps in unraveling the efficacy of molecular determinants still persist. Methodology: We compare two ERK2 inhibitors with different binding modes. A 5-7-Oxozeaenol is selective inhibitor which irreversibly binds ERK2 by the formation of covalent bond with Cys166 while 5-iodotubercidin binds noncovalently. Result & discussion: Covalent inhibition showed greater protein stability, favorable binding energetics (irreversible inhibition binding free energy [Delta G(bind)] = -40.4354 kcal/mol and reversible inhibition Delta G(bind) = -26.2515 kcal/mol); higher correlation in residual movement and multiple van der Waals interactions as evident from residue interaction analysis. Conclusion: This investigation of the different inhibition modes of ERK2 would assist toward the design of more potent and highly site-specific covalent inhibitors in cancer therapy. [GRAPHICS] .
引用
收藏
页码:1003 / 1015
页数:13
相关论文
共 50 条
  • [21] Expression of ERK1/ERK2 MAP kinase, protein kinase C, and AKT kinase in lymphoid malignant cells.
    Takahashi, T
    Murohashi, I
    Kishimoto, K
    Horibe, N
    Yagasaki, Y
    Itoh, Y
    Kawai, N
    Suzuki, T
    Matsuda, A
    Kusumoto, S
    Bessho, M
    Hirashima, K
    BLOOD, 1998, 92 (10) : 376A - 376A
  • [22] Regulation of mitogen-activated protein kinases ERK1 and ERK2
    Wolf, SC
    Klaussner, M
    Risler, T
    Brehm, BR
    PERFUSION, 2002, 15 (09): : 354 - +
  • [23] The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP
    Pettiford, SM
    Herbst, R
    ONCOGENE, 2000, 19 (07) : 858 - 869
  • [24] The ERK2 Mitogen-Activated Protein Kinase Regulates the Timing of Oligodendrocyte Differentiation
    Fyffe-Maricich, Sharyl L.
    Karlo, J. Colleen
    Landreth, Gary E.
    Miller, Robert H.
    JOURNAL OF NEUROSCIENCE, 2011, 31 (03): : 843 - 850
  • [25] Essential role for ERK2 mitogen-activated protein kinase in placental development
    Hatano, N
    Mori, Y
    Oh-Hora, M
    Kosugi, A
    Fujikawa, T
    Nakai, N
    Niwa, H
    Miyazaki, J
    Hamaoka, T
    Ogata, M
    GENES TO CELLS, 2003, 8 (11) : 847 - 856
  • [26] Expression of ERK1/ERK2 MAP kinase, protein kinase C and Akt kinase by lymphoid malignant cells.
    Murohashi, I
    Takahashi, T
    Ihara, N
    Wakao, D
    Yagasaki, F
    Nakamura, Y
    Kawai, N
    Matsuda, A
    Jinnai, I
    Bessho, M
    BLOOD, 2005, 106 (11) : 177B - 177B
  • [27] THE MITOGEN-ACTIVATED PROTEIN-KINASES, ERK1 AND ERK2
    COBB, MH
    HEPLER, JE
    CHENG, MG
    ROBBINS, D
    SEMINARS IN CANCER BIOLOGY, 1994, 5 (04) : 261 - 268
  • [28] The complete pathway for catalytic activation of the mitogen-activated protein kinase, ERK2
    Prowse, CN
    Deal, MS
    Lew, J
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (44) : 40817 - 40823
  • [29] The MAP-kinase ERK2 is a specific substrate of the protein tyrosine phosphatase HePTP
    Sherrie M Pettiford
    Ronald Herbst
    Oncogene, 2000, 19 : 858 - 869
  • [30] ACTIVITY OF THE MAP KINASE ERK2 IS CONTROLLED BY A FLEXIBLE SURFACE LOOP
    ZHANG, JD
    ZHANG, FM
    EBERT, D
    COBB, MH
    GOLDSMITH, EJ
    STRUCTURE, 1995, 3 (03) : 299 - 307